Seretide Inhaler 25 mikrograma + 250 mikrograma u jednoj dozi stlačeni inhalat, suspenzija
| Name | Seretide Inhaler 25 mikrograma + 250 mikrograma u jednoj dozi stlačeni inhalat, suspenzija |
|---|---|
| Marketing Authorisation Number | HR-H-572113579 |
| Active Substance | salmeterolksinafoat flutikazonpropionat |
| Composition | jedna inhalacijska doza sadržava 25 mikrograma salmeterola u obliku salmeterolksinafoata i 250 mikrograma flutikazonpropionata |
| Pharmaceutical Form | stlačeni inhalat, suspenzija |
| Manufacturer | Glaxo Wellcome Production, Evreux, Francuska Glaxo Wellcome S.A., Aranda de Duero, Burgos, Španjolska |
| Marketing Authorisation Holder | GlaxoSmithKline Trading Services Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irska |
| Marketing Authorisation Date | 20.08.2021 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/14-02/30 |
| Registration Number | 381-12-01/70-21-28 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | Medicinal product on medical prescription for renewable delivery |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | R03AK06 |
| Marketing status | Marketed |
| Shortage status | No shortage |
| SmPC | download |
| PL | download |
